Messmer K, Ring J, Hedin H, Richter W, Seemann C
Zentralbl Chir. 1978;103(15):978-85.
A prospective controlled trial during 1975 and 1976 has revealed that none of the colloids in clinical use (plasma protein solution, gelatine, hydroxyethylstarch and dextran) is free from the risk of anaphylactoid reactions. Even though the incidence of anaphylactoid reactions is low (0.03%), lethal outcome might be encountered. Between the colloids differences exist as far as manifestation (skin, circulatory and respiratory system) and degree of severity (I--IV) of anaphylactoid reactions are concerned. Since the underlying pathomechanisms have not been elucidated yet, true prophylactic measures are unknown. Therefore, it is mandatory to control the patient very carefully at the beginning of infusion; early symptoms of anaphylactoid reactions should trigger immediate therapeutic measures. Recent findings showed that the anaphylactoid reactions to dextran might be elicited by immune complexes. A new model was developed to investigate the chances of specific prophylactic procedures.
一项在1975年至1976年期间进行的前瞻性对照试验表明,临床使用的胶体(血浆蛋白溶液、明胶、羟乙基淀粉和右旋糖酐)均存在类过敏反应风险。尽管类过敏反应的发生率较低(0.03%),但仍可能出现致命后果。就类过敏反应的表现(皮肤、循环和呼吸系统)和严重程度(I - IV级)而言,胶体之间存在差异。由于潜在的发病机制尚未阐明,真正的预防措施尚不清楚。因此,在输液开始时必须非常仔细地观察患者;类过敏反应的早期症状应触发立即的治疗措施。最近的研究结果表明,对右旋糖酐的类过敏反应可能由免疫复合物引发。开发了一种新模型来研究特定预防程序的可能性。